HYBRIDOMA CELLS PRODUCING ANTIBODIES AGAINST A-CHAIN OF MISTLETOE LECTIN-I ARE RESISTANT TO THIS TOXIN

被引：8

作者：

TONEVITSKY, AG ^{[1
]}

SHAMSHIEV, AT ^{[1
]}

PROKOPHEV, SA ^{[1
]}

AGAPOV, LI ^{[1
]}

TOPTYGIN, AY ^{[1
]}

机构：

[1] MINIST HLTH,INST IMMUNOL,MOSCOW 115478,RUSSIA

来源：

IMMUNOLOGY LETTERS | 1995年 / 46卷 / 1-2期

关键词：

MISTLETOE LECTIN I; HYBRIDOMA; MECHANISM OF ACTION;

D O I：

10.1016/0165-2478(95)00011-S

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The cytotoxic effect of mistletoe lectin I (MLI) on TA5 hybridoma cells which produce monoclonal antibodies (mAb) to MLI A-chain (MLA) was investigated. In vitro cytotoxic tests with colorimetric assay were carried out for LD(50) determination. TA5 hybridoma cells were 100 times more resistant to MLI and 30 times to chimeric toxin consisting of MLA and ricin B-chain (MLA/RTB) than control cells. The TA5 mAb (IgG1) recognized MLI A-chain in Western blotting and bound I-125-labeled MLI with K-a of 0.43 X 10(8) M(-1) The TA5 and control hybridomas had the same number of I-125-labeled MLI binding sites. Therefore cell-surface TA5 antibodies did not influence MLI binding with the cell. The cytotoxic effect and binding of MLI were completely blocked in the presence of 20 mM lactose. Thus, MLI cytotoxicity was mediated only by cell-surface galactosyl residues; intracellular mAb molecules block MLI toxicity. Our data suggest that MLA molecules mediating cytotoxicity pass through an anti-MLA. antibody-containing vesicular compartment and that mAbs inhibit the translocation activity of MLI A-chain from intracellular vesicles into the cytosol.

引用

页码：5 / 8

页数：4

共 21 条

[1]

Franz, Oncology, 43, (1986)

[2]

Olsnes, Stirpe, Sandvig, Pihl, J. Biol. Chem., 257, (1982)

[3]

Debray, Wieruszeski, Strecker, Franz, Carbohydrate Res., 236, (1992)

[4]

Wu, Chin, Franz, Pfuller, Herp, Biochim. Biophys. Acta, 1117, (1992)

[5]

Endo, Tsurugi, Franz, FEBS Lett., 231, (1988)

[6]

Mellman, Simmons, Cell, 68, (1992)

[7]

Dunphy, Rothman, Cell, 42, (1985)

[8]

Yoshida, Zhang, Chen, Franz, Wu, Pharmazie, 46, (1991)

[9]

Tonevitsky, Toptygin, Pfuller, Bushueva, Ershova, Gelbin, Pfuller, Agapov, Franz, Int. J. Immunopharmacol., 13, (1991)

[10]

Wiedlocha, Sandvig, Walzel, Radzikowsky, Olsnes, Cancer Res., 51, (1991)

← 1 2 3 →